Trial Profile
Phase II Trial of Abiraterone Acetate in Patients With Relapsed and/or Metastatic, Castration Resistant Salivary Gland Cancers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Adenocarcinoma; Salivary gland cancer
- Focus Therapeutic Use
- 01 Oct 2021 Primary endpoint (Response rate) has been met, according to Results published in the Journal of Clinical Oncology.
- 01 Oct 2021 Results published in the Journal of Clinical Oncology
- 01 Mar 2021 Status changed from recruiting to completed.